Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: Deciphering the molecular basis of the kinase inhibitors selectivity

Proteins: Structure, Function and Genetics

Volumn 66, Issue 4, 2007, Pages 912-929

  Verkhivker, Gennady M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Binding dynamics; Energy landscapes; In silico profiling; Kinase selectivity; Protein tyrosine kinases; Pyrido 2,3 d pyrimidine inhibitors

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE;

ARTICLE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG TARGETING; ENERGY; ENZYME INHIBITION; ENZYME STRUCTURE; LIGAND BINDING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BINDING SITES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTEOME; PROTEOMICS; STRUCTURAL HOMOLOGY, PROTEIN; SUBSTRATE SPECIFICITY;

EID: 33847033749     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21287     Document Type: Article

References (156)

1. Kuriyan J, Cowburn D. Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 1997;26:259-288.
2. Pawson T. Protein modules and signaling networks. Nature 1995;373:573-580.
3. Thomas AM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Biol 1997;13:513-609.
4. Hunter T, Plowman GD. Review: the protein kinases of budding yeast: six score and more. Trends Biochem Sci 1997;22: 18-22.
5. Hunter T. Signaling 2000 and beyond. Cell 2000;100:113-127.
6. Hanks SK, Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995;9:576-596.
7. Kostich M, English J, Madison V, Gheyas F, Wang L, Qiu P, Greene J, Laz TM. Human members of the eukaryotic protein kinase family. Genome Biol 2002;3:research0043.10043. 12.
8. Krupa A, Srinivasan N. The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations. Genome Biol 2002;3:research0066.10066.14
9. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-1934.
10. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 2002;10:514-520.
11. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373-398.
12. Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol 2002;12: 735-741.
13. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365.
14. Sridhar R, Hanson-Painton O, Cooper DR. Protein kinases as therapeutic targets. Pharm Res 2000;17:1345-1353.
15. Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004;37:618-635.
16. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
17. Schlessinger J. Signal transduction. Autoinhibition control. Science 2003;300:750-752.
18. Toledo LM, Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 1999;6:775-805.
19. Toogood PL. Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 2001;21:487-498.
20. Sawyer T, Boyce B, Dalgarno D, Iuliucci J. Src inhibitors: genomics to therapeutics. Expert Opin Investig Drugs 2001; 10:1327-1344.
21. Fischer PM. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr Med Chem 2004;11:1563-1583.
22. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17:2998-3010.
23. Sawyer TK. Novel oncogenic protein kinase inhibitors for cancer therapy. Curr Med Chem Anticancer Agents 2004;4:449-455.
24. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371: 199-204.
25. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005;12:621-637.
26. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 2005;10:839-846.
27. Vulpetti A, Bosotti R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco 2004;59:759-765.
28. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 2004;1697:243-257.
29. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 2003;4:963-971.
30. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423.
31. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003;17:1211-1262.
32. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004;91:1-30.
33. Lydon NB, Druker BJ. Lessons learned from the development of imatinib. Leuk Res 2004;28 (Suppl 1):S29-S38.
34. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22:247-306.
35. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2653.
36. Yao H, Kristensen DM, Mihalek I, Sowa ME, Shaw C, Kimmel M, Kavraki L, Lichtarge O. An accurate, sensitive, and scalable method to identify functional sites in protein structures. J Mol Biol 2003;326:255-261.
37. Glaser F, Pupko T, Paz I, Bell RE, Bechor-Shental D, Martz E, BenTal N. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 2003;19:163-164.
38. Panchenko AR, Kondrashov F, Bryant S. Prediction of functional sites by analysis of sequence and structure conservation. Protein Sci 2004;13:884-892.
39. Cheng G, Qian B, Samudrala R, Baker D. Improvement in protein functional site prediction by distinguishing structural and functional constraints on protein family evolution using computational design. Nucleic Acids Res 2005;33:5861-5867.
40. Pils B, Copley RR, Schultz J. Variation in structural location and amino acid conservation of functional sites in protein domain families. BMC Bioinformatics 2005;6:210.
41. Glaser F, Morris RJ, Najmanovich RJ, Laskowski RA, Thornton JM. A method for localizing ligand binding pockets in protein structures. Proteins 2006;62:479-488.
42. Verkhivker GM. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases. Bioinformatics 2006;22:1846-1854.
43. Huse M, Kuriyan J The conformational plasticity of protein kinases. Cell 2002;109:275-282
44. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303:1800-1805.
45. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases: controlling activity through activation segment conformation. Mol Cell 2004;15:661-75.
46. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994;372:746-754.
47. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997;16:5572-5581.
48. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999;3:629-638.
49. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999;3:639-648.
50. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-272.
51. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
52. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-31663.
53. Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005;13:861-871.
54. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Home E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-6659.
55. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-1942.
56. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62:4236-4243.
57. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-843.
58. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003;112:845-857.
59. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112:859-871.
60. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44.
61. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, Muller-Dieckmann HJ, Nienaber VL, Noland BW, Post K, Rajashankar KR, Ramos A, Russell M, Burley SK, Buchanan SG. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004;279:55827-55832.
62. Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005;13:861-871.
63. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-1149.
64. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 2006;21:787-798.
65. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;6:1007-1014.
66. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-5797.
67. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, Karplus M, Cole PA, Kuriyan J. A SRC-like inactive conformation in the ABL tyrosine kinase domain. PLoS Biol 2006;4:0753-0767.
68. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002;99:10700-10705.
69. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
70. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003;22:7389-7395.
71. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4614.
72. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
73. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004;4:285-299.
74. Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, Peschel C, Duyster J. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006;20:650-657.
75. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003;100:15434-15439.
76. Godl K, Daub H. Proteomic analysis of kinase inhibitor selectivity and function. Cell Cycle 2004;3:393-395.
77. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H. Cellular targets of gefitinib. Cancer Res 2005;65:379-382.
78. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23: 329-336.
79. McCammon JA. Target flexibility in molecular recognition. Biochim Biophys Acta 2005;1754:221-224.
80. Sims PA, Wong CF, Vuga D, McCammon JA, Sefton BM. Relative contributions of desolvation, inter- and intramolecular interactions to binding affinity in protein kinase systems. J Comput Chem 2005;26:668-681.
81. Rockey WM, Elcock AH. Rapid computational identification of the targets of protein kinase inhibitors. J Med Chem 2005;48: 4138-4152.
82. Sheinerman FB, Giraud E, Laoui A. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J Mol Biol 2005;352: 1134-1156.
83. Ortiz AR, Gomez-Puertas P, Leo-Macias A, Lopez-Romero P, Lopez-Vinas E, Morreale A, Murcia M, Wang K. Computational approaches to model ligand selectivity in drug design. Curr Top Med Chem 2006;6:41-55.
84. Wong CF, Kua J, Zhang Y, Straatsma TP, McCammon JA. Molecular docking of balanol to dynamics snapshots of protein kinase A. Proteins 2005;61:850-858.
85. Ferrari AM, Wei BQ, Costantino L, Shoichet BK. Soft docking and multiple receptor conformations in virtual screening. J Med Chem 2004;47:5076-5084.
86. Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol 2004; 337:209-225.
87. Cavasotto CN, Kovacs JA, Abagyan RA. Representing receptor flexibility in ligand docking through relevant normal modes. J Am Chem Soc 2005;127:9632-9640.
88. Wei BQ, Weaver LH, Ferrari AM, Matthews BW, Shoichet BK. Testing a flexible-receptor docking algorithm in a model binding site. J Mol Biol 2004;337:1161-1182.
89. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 1997;40:2296-22303.
90. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM. 2-Substituted aminopyrido[2,3-d] pyrimidin-7(8H)-ones structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998;41:3276-3292.
91. Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klohs WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H, Doherty AM. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem 1998;41:4365-4377.
92. Hamby JM, Showalter HD. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:169-193.
93. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d] pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000;60:885-898.
94. Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J Med Chem 2001;44:1915-1926.
95. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 1999;59:6145-6152.
96. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Muller S, Daub H. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics 2004;3:1181-1193.
97. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000;60:3127-3131.
98. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002;62:4244-4255.
99. von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003;63:6395-6404.
100. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002;62: 7149-7153.
101. Dorsey JF, Cunnick JM, Lanehart R, Huang M, Kraker AJ, Bhalla KN, Jove R, Wu J. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002; 16:1589-1595.
102. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003;9:1267-1273.
103. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005;105:1652-1659.
104. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL, Jr. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 2005;105: 3995-4003.
105. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-11016.
106. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.
107. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 2005;106:227-234.
108. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102:3395-3400.
109. Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103:9244-9249.
110. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242.
111. Mirny L, Shakhnovich E. Protein folding theory: from lattice to all-atom models. Annu Rev Biophys Biomol Struct 2001;30: 361-396.
112. Onuchic JN, Wolynes PG. Theory of protein folding. Curr Opin Struct Biol 2004;14:70-75.
113. Shoemaker BA, Portman JJ, Wolynes PG. Speeding molecular recognition by using the folding funnel: the fly-casting mechanism. Proc Natl Acad Sci USA 2000;97:8868-8873.
114. Levy Y, Wolynes PG, Onuchic J. Protein folding topology determines binding mechanism. Proc Natl Acad Sci USA 2004;101:511-516.
115. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Simulating disorder-order transitions in molecular recognition of unstructured proteins: where folding meets binding. Proc Natl Acad Sci USA 2003;100:5148-5153.
116. Onuchic JN, Nymeyer H, Garcia AE, Chahine J, Socci ND. The energy landscape theory of protein folding: insights into folding mechanisms and scenarios. Adv Protein Chem 2000; 53:87-152
117. Plotkin SS, Onuchic JN. Understanding protein folding with energy landscape theory. Part I: Basic concepts. Q Rev Biophys 2002;35:111-167.
118. Plotkin SS, Onuchic JN. Understanding protein folding with energy landscape theory. Part II: Quantitative aspects. Q Rev Biophys 2002;35:205-286.
119. Wolynes PG. Energy landscapes and solved protein-folding problems. Philos Transact A Math Phys Eng Sci 2005;363: 453-464.
120. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Curr Opin Struct Biol 2002;12:197-203.
121. Tsai C-J, Kumar S, Ma B, Nussinov R. Folding funnels, binding funnels and protein function. Protein Sci 1999;8:1181-1190.
122. Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R. Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci 2000;9:10-19.
123. Mayo SL, Olafson BD, Goddard WA, III. DREIDING: a generic force field for molecular simulation. J Phys Chem 1990;94:8897-8909.
124. Weiner SJ, Kollman PA, Case DA, Singh UC, Chio C, Alagona G, Profeta S, Weiner P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 1984;106:765-784.
125. Cornell WD, Cieplak P, Bayly CL, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox ,T, Caldwell JW, Kollman PA. A second generation force field for simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995; 117:5179-5197.
126. Stouten PFW, Frömmel C, Nakamura H, Sander C. An effective solvation term based on atomic occupancies for use in protein simulations. Mol Simul 1993;10:97-120.
127. Beutler TC, Mark AE, van Schaik RC, Gerber PR, van Gunsteren W. Avoiding singularities and numerical instabilities in free energy calculations based on molecular simulations. Chem Phys Lett 1994;222:529-539.
128. Marinari E, Parisi G. Simulated tempering: a new Monte Carlo scheme. Europhys Lett 1992;19:451-458.
129. Hukushima K, Nemoto K. Exchange Monte Carlo method and application to spin glass simulations. J Phys Soc (Jap) 1996;65:1604-1607.
130. Hansmann UHE, Okamoto Y. Monte Carlo simulations in generalized ensemble: multicanonical algorithm versus simulated tempering. Phys Rev E 1996;54:5863-5865.
131. Hansmann UHE, Okamoto Y. Generalized-ensemble Monte Carlo method for systems with rough energy landscape. Phys Rev E 1997;56:2228-2233.
132. Hansmann UHE, Okamoto Y. Numerical comparisons of three recently proposed algorithms in the protein folding problem. J Comput Chem 1997;18:920-933.
133. Hansmann UHE. Parallel tempering algorithm for conformational studies of biological molecules. Chem Phys Lett 1997; 281:140-150.
134. Sugita Y, Okamoto Y. Replica-exchange molecular dynamics method for protein folding. Chem Phys Lett 1999;314:141-151.
135. Verkhivker GM, Rejto PA, Bouzida D, Arthurs S, Colson AB, Freer ST, Gehlhaar DK, Larson V, Luty BA, Marrone T, Rose PW. Navigating ligand-protein binding free energy landscapes: universality and diversity of protein folding and molecular recognition mechanisms. Chem Phys Lett 2001;336: 495-503.
136. Bouzida D, Kumar S, Swendsen RH. Efficient Monte Carlo methods for the computer simulation of biological molecules. Phys Rev A 1992;45:8894-8901.
137. Still WC, Tempczyk A, Hawley RC, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990;112:6127-6129.
138. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T, Still WC. MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990;11:440-467.
139. Qiu D, Shenkin PS, Hollinger FP, Still WC. The GB/SA continuum model for solvation. A fast analytical method for the calculation of approximate born radii. J Phys Chem A 1997; 101:3005-3014.
140. Weiser J, Weiser AA, Shenkin PS, Still WC. Neighbor-list reduction: optimization for computation of molecular van der Waals and solvent-accessible surface areas. J Comput Chem 1998;19:797-808.
141. Weiser J, Weiser AA, Shenkin PS, Still WC. Erratum: Neighbor-list reduction: optimization for computation of molecular van der Waals and solvent-accessible surface areas. J Comput Chem 1998;19:1110.
142. Weiser J, Shenkin PS, Still WC. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem 1999;20:217-230.
143. Weiser J, Shenkin PS, Still WC. Fast, approximate algorithm for detection of solvent-inaccessible atoms. J Comput Chem 1999;20:586-596.
144. Srinivasan J, Cheatham TE, Cieplak P, Kollman PA, Case DA. Continuum solvent studies of the stability of DNA, RNA and phosphoramidate-DNA helices. J Am Chem Soc 1998; 120:9401-9409.
145. Massova I, Kollman PA. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J Am Chem Soc 1999;121:8133-8143.
146. Chong LT, Duan Y, Wang L, Massova I, Kollman PA. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc Natl Acad Sci USA 1999; 96:14330-14335.
147. Kuhn B, Kollman PA. A ligand that is predicted to bind better to avidin than biotin: insights from computational fluorine scanning. J Am Chem Soc 2000;122:3909-3916.
148. Kuhn B, Kollman PA. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J Med Chem 2000; 43:3786-3791.
149. Lee MR, Duan Y, Kollman PA. Use of MM-PB/SA in estimating the free energies of proteins: application to native, intermediates, and unfolded villin headpiece. Proteins 2000;39: 309-316.
150. Wang W, Kollman PA. Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model. J Mol Biol 2000;303:567-582.
151. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE, III. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889-897.
152. Tsui V, Case DA. Molecular dynamics simulations of nucleic acids with a generalized Born solvation model. J Amer Chem Soc 2000;122:2489-2498.
153. Taylor R. Life-science applications of the Cambridge Structural Database. Acta Crystallogr D Biol Crystallogr 2002;58: 879-888.
154. Lovell SC, Word JM, Richardson JS, Richardson DC. The penultimate rotamer library. Proteins 2000;40:389-408.
155. Moriarty KJ, Koblish HK, Garrabrant T, Maisuria J, Khalil E, Ali F, Petrounia IP, Crysler CS, Maroney AC, Johnson DL, Galemmo RA, Jr. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of aurora-A kinase inhibitors. Bioorg Med Chem Lett 2006;16:5778-5783.
156. Harrington EA, Bebbington D, Moore J, Rasmussen RK, AjoseAdeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10: 262-267.